Sagimet Biosciences
SGMT· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +31.6% in FY2025
David Happel is the CEO of Sagimet Biosciences and was paid $3.2M in FY2025 (Dec), up 258%.
Pay$100 in the stock at the end of FY23 → $109
Executives3
See all- 1David HappelPresident and Chief Executive OfficerFY2025
- 2Elizabeth Rozek, Esq.Chief Legal and Administrative OfficerFY2025
- 3Eduardo Bruno Martins, M.D., D.Phil.Former Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSagimet Biosciences paid its 3 named executives $6.1M in total in FY2025 (Dec). CEO David Happel was paid $3.2M of that.
| Name | |||
|---|---|---|---|
| David HappelPresident and Chief Executive Officer | |||
| Elizabeth Rozek, Esq.Chief Legal and Administrative Officer | Not disclosed | ||
| Eduardo Bruno Martins, M.D., D.Phil.Former Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Sagimet Biosciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 21, 2026 | FY2025 |
| Annual report | 10-K | Mar 11, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 12, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 18, 2024 | FY2023 |
| Annual report | 10-K | Mar 25, 2024 | FY2023 |
